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Abstract	
Findings from a recent study describing prevalence of common disease conditions in the largest
documented cohort of individuals with Down syndrome (DS) in the United States strongly suggested
significant disparity in endocrine disorders among these individuals when compared with age- and sexmatched individuals without DS. This retrospective, descriptive study is a follow-up report documenting
prevalence of 21 endocrine disorder conditions, across 28 years of data, from 6078 individuals with DS
and 30,326 age- and sex-matched controls, abstracted from electronic medical records within a large
integrated health system.
Overall, individuals with DS experienced higher prevalence of adrenal insufficiency and Addison’s
disease; thyroid disorders, including hypothyroidism, hyperthyroidism, Hashimoto’s disease, and
Graves’ disease; prolactinoma/hyperprolactinemia; diabetes insipidus; type I diabetes mellitus; and
gout. Conversely, those with DS had lower prevalence of polycystic ovary syndrome and type II
diabetes mellitus. Many prevalences of endocrine conditions seen in individuals with DS significantly
differ relative to their non-DS matched counterparts. These varied findings warrant further exploration
into how screening for and treatment of endocrine conditions may need to be approached differently
for individuals with DS. (J Patient Cent Res Rev. 2022;9:70-74.)
Keywords	
Down syndrome; prevalence; endocrine diseases; thyroid disorder; diabetes mellitus; adrenal
insufficiency

A

recent study of the largest documented cohort
of individuals with Down syndrome (DS) in
the United States described the prevalence of a
broad range of disease conditions.1 Findings strongly
suggested significant disparity in endocrine-specific
conditions among individuals with DS as compared with
age- and sex-matched individuals without DS.1 It is wellsupported in current research that thyroid disorder and
diabetes mellitus, specifically, are more prevalent among
individuals with DS, meriting a closer look at these and
other endocrine conditions.2-7
To explore respective prevalence of a more comprehensive
set of endocrine conditions among individuals with
DS, this follow-up brief report to a broader study1
utilizes clinical data representing the largest sample of
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individuals with DS in the United States, treated across a
single Midwestern integrated health system that includes
the largest center of care for adolescents and adults with
DS. The objective was to provide critical information
on endocrine-specific conditions in individuals with
DS, thereby adding to the sparsely available clinical
research into this unique but growing patient population
and ultimately to enhance practitioner knowledge and
specialized care.

METHODS

This retrospective, descriptive cohort study utilized 28
years of available inpatient and outpatient encounter data
(May 1991–September 2019) abstracted from electronic
medical records of one of the largest nonprofit health
systems in the United States. As a follow-up to a larger
study conducted with this patient population, it was
determined to be non-human subjects research by the
local institutional review board. Full details on the data
collection methods for this and the more generalized
prevalence study can be found in the previously published
parent report.1
Brief Report

Participants

In all, 6078 eligible cases with at least 1 encounter with
an International Classification of Diseases (ICD) code of
DS were identified. Controls included up to 5 individuals
without a diagnosis of DS matched to each case on year
of birth (±1 year) and sex by a data analyst. There were
30,326 eligible controls. Overall, 64 cases were assigned
only 4 (as opposed to 5) matched controls.
Procedures

Preidentified endocrine conditions of interest among
individuals with DS were chosen based on the existing
literature as well as clinical expertise and experience, with
corresponding ICD codes reviewed by a clinical expert
(B.C.). To assess prevalence, this study used the U.S.
Clinical Modification (CM) codes for medical diagnoses
based on the statistical classification of disease denoted
in the World Health Organization’s publication of the

ICD.8 Specifically, 10th Revision (ICD-10-CM) and 9th
Revision (ICD-9-CM) codes were utilized. See Table 1
for a complete list of endocrine-specific conditions of
interest and associated ICD codes.
Statistical Methods

Demographics are reported as means with standard
deviations and medians with ranges for age and total
encounters per sample. Sex, race, ethnicity, and
insurance type are reported as counts with percentages.
Clinical conditions are reported as counts with
percentages and odds ratios (OR) representing the
odds of cases having an endocrine condition relative to
controls. Corresponding Pearson’s chi-squared P-values
represent statistically significant differences (at an alpha
of <0.05) in prevalence of diagnoses between cases and
controls. Fisher’s exact P-value was interpreted when
any sample count was less than 5.

Table 1. Endocrine Conditions of Interest and Associated Codes
Endocrine condition
Acromegaly
Panhypopituitarism
Adrenal insufficiency/Addison’s disease
Cushing’s syndrome and increased adrenal function
Cystic fibrosis
Creutzfeldt-Jakob disease
Hypothyroidism
Hashimoto's disease
Hyperthyroidism
Graves’ disease
Multiple endocrine neoplasia type 1
Polycystic ovary syndrome
Hyperparathyroidism
Hypoparathyroidism
Prolactinoma/Hyperprolactinemia
Turner syndrome
Diabetes insipidus
Secondary diabetes mellitus
Type I diabetes mellitus

Type II diabetes mellitus

ICD-10-CM codes

ICD-9-CM codes

E220
E230
E27
E24
E84
A810
E02, E030–E033, E038,
E039, E063, E890
E063
E05
E050
E3120–E3123
E282
E210
E209
E221
Q96
E232, N251
E089, E099
E109, E1065, E1069

2530
2522
2554, 25541, 25542, 2555
2550, 2551, 2553
27700
04619
243, 244, 2452

E119, E1165, E1169

Gout

M10

2452
242
2420
25801, 25802, 25903
2564
25200, 25201, 25202, 58881
2521
2521
7586
2535, 5881
249
25001, 25003, 25211, 25013,
25021, 25023, 25031, 25033,
25041, 25043, 25051, 25053,
25061, 25063, 25071, 25073,
25081, 25083, 25091, 25093
25000, 25002, 25010, 25012,
25020, 25022, 25030, 25032,
25040, 25042, 25050, 25052,
25060, 25062, 25070, 25072,
25080, 25082, 25090, 25092
2740, 2741, 2748, 2749

CM, Clinical Modifications; ICD, International Classification of Diseases.
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RESULTS

The DS case population was predominantly White
(77.35%) and of non-Hispanic/Latino ethnicity (73.51%).
Cases had a median of 6 total encounters (ie, clinical
visits in the health system) in the dataset. The control
population was also predominantly White (61.97%) and
of non-Hispanic/Latino ethnicity (81.72%), with a median
of 7 total encounters in the dataset. Both groups were
approximately 52% male and had a median age of 25
years. For complete demographics of the DS and matched
control cohorts, the reader is referred to the relevant table
published within the parent article describing this project.1
Table 2 of this brief report displays complete results for
all endocrine conditions analyzed. Statistically significant
findings of OR (95% CI) and P-value derived from
comparing prevalence of clinical endocrine conditions of
interest among individuals with DS (ie, cases) to matched
controls are highlighted in the following paragraphs.
Relative to controls, individuals with DS had greater
odds of experiencing adrenal insufficiency (OR: 1.68
[1.18, 2.40]; P=0.0037); hypothyroidism (OR: 10.94

[10.17, 11.78]; P<0.0001); hyperthyroidism (OR: 2.46
[2.03, 2.99]; P<0.0001); Hashimoto’s disease (OR: 2.41
[1.80, 3.21]; P<0.0001); Graves’ disease (OR: 1.89 [1.22,
2.93]; P=0.0035); prolactinoma/hyperprolactinemia (OR:
2.60 [1.33, 5.08]; P=0.0038); diabetes insipidus (OR:
2.91 [1.15, 7.40]; P=0.0185); type I diabetes mellitus
(OR: 1.63 [1.23, 2.15]; P=0.0005); and gout (OR: 2.67
[2.29, 3.10]; P<0.0001).
Other statistically significant results revealed that,
relative to controls, individuals with DS had lesser odds
of experiencing polycystic ovary syndrome (OR: 0.48
[0.28, 0.81]; P=0.0049) and type II diabetes mellitus
(OR: 0.56 [0.49, 0.64]; P<0.0001).

DISCUSSION

These findings show that prevalences of endocrine
disorders seen in individuals with DS vastly differ from
their non-DS matched counterparts. While it is a challenge
to draw a widespread conclusion about comorbidities in
individuals with DS, generally speaking, it is reasonable
to conclude that care for individuals with DS should
not mirror recommendations or clinical guidelines for

Table 2. Prevalence of Endocrine Conditions Among Cases vs Controls
Endocrine condition
Acromegaly
Panhypopituitarism
Adrenal insufficiency/Addison’s disease
Cushing’s syndrome and increased adrenal function
Cystic fibrosis
Creutzfeldt-Jakob disease
Hypothyroidism
Hashimoto's disease
Hyperthyroidism
Graves’ disease
Multiple endocrine neoplasia type 1
Polycystic ovary syndrome
Hyperparathyroidism
Hypoparathyroidism
Prolactinoma/Hyperprolactinemia
Turner syndrome
Diabetes insipidus
Secondary diabetes mellitus
Type I diabetes mellitus
Type II diabetes mellitus
Gout

DS sample
(n=6078)
0
8
41
0
4
0
2212
69
155
28
0
15
3
3
13
1
7
6
66
240
261

a

Statistical significance was reached at an alpha of <0.05.

b

Fisher’s exact test P-value was interpreted due to low sample count.

Controls
(n=30,326)
0
51
122
11
6
0
1507
144
319
74
1
157
45
9
25
10
12
19
203
2066
502

OR (95% CI)
–
0.78 (0.37, 1.65)
1.68 (1.18, 2.40)
–
3.33 (0.94, 11.80)
–
10.94 (10.17, 11.78)
2.41 (1.80, 3.21)
2.46 (2.03, 2.99)
1.89 (1.22, 2.93)
–
0.48 (0.28, 0.81)
0.33 (0.10, 1.07)
1.66 (0.45, 6.15)
2.60 (1.33, 5.08)
0.50 (0.06, 3.90)
2.91 (1.15, 7.40)
1.58 (0.63, 3.95)
1.63 (1.23, 2.15)
0.56 (0.49, 0.64)
2.67 (2.29, 3.10)

Pa
–
0.5179
0.0037
0.2301b
0.0701b
–
<0.0001
<0.0001
<0.0001
0.0035
1.0000b
0.0049
0.0524b
0.4353b
0.0038
0.7038b
0.0185
0.3273
0.0005
<0.0001
<0.0001

DS, Down syndrome; OR, odds ratio.
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screening, prevention, diagnoses (including assessment
of pretest probability), or treatment for the general U.S.
population and, instead, should reflect the unique needs
and common comorbidities of this population.
Our parent study found that individuals with DS had
lower prevalence of overall diabetes mellitus relative to
age- and sex-matched counterparts without DS.1 Other
studies have shown an increased prevalence of type
I diabetes among individuals with DS.6,7 Previously
reported data are less clear on prevalence of type II
diabetes, with studies showing increased, similar, and
decreased rates as compared to those without DS.2,6
The coding framework used in this study allowed us to
separate ICD codes by type, which did then demonstrate
that while type I diabetes is more common in those with
DS, type II diabetes is less common. This is despite the
parent study showing obesity is more common in people
with DS.3 Moreau et al provided a review of factors that
may clarify our findings, including that obesity is often
related to functional differences in multiple hormones
and that, despite more obesity in those with DS, other
factors could be associated with lesser type II diabetes
found in this study.9
Etiology or cause for the differences in prevalence of
endocrine conditions, including diagnosis differences,
were not explored in this study. For instance, the
diagnosis of gout, which has traditionally been thought of
as a rheumatologic disorder but was included here due to
its possible link to metabolic syndrome,10 highlights some
of the challenges of diagnostic accuracy in individuals
with DS. Specifically, individuals with DS tend to have
higher levels of serum uric acid,11 but compliance with
an arthrocentesis to examine joint fluid to confirm the
diagnosis can be limited among this patient population.
This can result in a presumptive, rather than confirmed,
diagnosis based on elevated serum uric acid and the
clinical picture.
While these prevalence findings highlight a need for
remodeled care specific to individuals with DS, it also
compels new research. For one, a deeper investigation
into the broad range of more and less prevalent endocrine
conditions, and the reasons and etiologies behind those
differences, could be informative. Furthermore, the
variations in prevalence warrant exploration into how
screening and treatment for endocrine conditions may
need to be different for individuals with DS. Finally,
further analysis of the effects of endocrine disorders,
specifically thyroid disorder and diabetes, in people with
DS is required to better understand if certain condition
subtypes are driving the findings seen in this work.

Brief Report

Strengths/Limitations

Our study’s patient sample is one of the largest to
date overall, and particularly in the United States, in
which prevalence of disease conditions in individuals
with DS was investigated, making it suitable for the
analysis of relatively rare morbidities of interest. Our
dataset incorporated the earliest available clinical data,
representing a 28-year time span, which allowed for a
very comprehensive look at prevalence. Our analysis
also included a large group of controls matched by age
and sex, a sample that can be representative of patients
without DS in the United States.
While these findings represent data from only one U.S.
Midwest-based health system, the consistency of data
collected from a single large system may provide the most
accurate and available review of prevalence among a DS
sample population, given the United States’ fragmented
storage of data. Of importance, 34% of our DS cohort
were seen by our institution’s DS care center, likely a
higher ratio of specialized care than that provided by most
U.S. health systems without a large, centralized, dedicated
DS clinic. This fact may have led to comparatively better
diagnostic accuracy of ICD coding and, subsequently,
more precise prevalence findings among individuals
with DS. It should be noted that diagnostic accuracy in
the setting of DS in general can be difficult for a variety
of reasons, including limitations of some patients’ ability
to cooperate with evaluations, limited communication
skills in some patients, and differences in presentations
of some conditions.12 While the codes used to represent
the conditions of interest in this study were carefully
chosen and reviewed by a clinical expert on DS, it is
acknowledged that these codes may not be ones most
commonly used to represent corresponding conditions. It
is also possible that these codes over- or underrepresent
diagnoses among individuals with DS relative to those
without DS.
Although our study included both youths and adults with
DS when determining prevalence of endocrine disorders,
patterns of occurrence over time were not analyzed.
Future research should look at conditions across time,
report on youths and adults separately, and track the
course of conditions seen at different stages of the
increasing lifespan of individuals with DS.

CONCLUSIONS

In this endocrine condition-focused follow-up report to a
previously published study of comprehensive differences
in disease conditions prevalent among individuals
with Down syndrome relative to matched controls,1
numerous differences between cohorts were identified.

aah.org/jpcrr

73

Adrenal insufficiency, thyroid disorders, prolactinoma/
hyperprolactinemia, diabetes insipidus, type I diabetes
mellitus, and gout, were significantly more prevalent
in individuals with DS. Polycystic ovary syndrome and
type II diabetes mellitus were significantly less prevalent.
This information can be used to better guide practitioners,
enhance specialized DS care, and potentially change
screening protocols for this unique population.
Patient-Friendly Recap
• Broader research previously reported by the
authors suggested various endocrine disorders
may be more or less prevalent in individuals with
Down syndrome (DS).
• To better characterize this population, authors
used patient records from a single health system
to compare diagnosis of endocrine conditions in
those with DS to a control cohort of similar patients
without DS.
•M
 ost significantly, individuals with DS were more
likely to have thyroid disorders, type I diabetes, and
gout and less likely to have type II diabetes than
their age- and sex-matched counterparts.
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